Ida Sim

Ida Sim

Auto-generated profile, based on publicly available information

Ida Sim

Division of General Internal Medicine, University of California, San Francisco, Box 0320, San Francisco, CA, 94143, United States, 1-415-353-7922

Research Focus & Metrics

Academic Career Length

21Years (2006-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
5 September 2019 in New England Journal of Medicine
Verified
Journal Article
Closed access
ISIda Sim
Ida Sim
Mobile health involves sensors, mobile apps, social media, and location-tracking technology used in disease diagnosis, prevention, and management. This article provides an overview of key functional and regulatory aspects; the article is accompanied by an explanatory video, an illustrated glossary, and an audio interview with the author.

23 September 2008 in PLOS Medicine
Verified
Journal Article
Open access
PDF file
KLKirby Lee
Kirby Lee
PBPeter Bacchetti
Peter Bacchetti
ISIda Sim
Ida Sim
The United States (US) Food and Drug Administration (FDA) approves new drugs based on sponsor-submitted clinical trials. The publication status of these trials in the medical literature and factors associated with publication have not been evaluated. We sought to determine the proportion of trials submitted to the FDA in support of newly approved drugs that are published in biomedical journals that a typical clinician, consumer, or policy maker living in the US would reasonably search. We conducted a cohort study of trials supporting new drugs approved between 1998 and 2000, as described in FDA medical and statistical review documents and the FDA approved drug label. We determined publication status and time from approval to full publication in the medical literature at 2 and 5 y by searching PubMed and other databases through 01 August 2006. We then evaluated trial characteristics associated with publication. We identified 909 trials supporting 90 approved drugs in the FDA reviews, of which 43% (394/909) were published. Among the subset of trials described in the FDA-approved drug label and classified as “pivotal trials” for our analysis, 76% (257/340) were published. In multivariable logistic regression for all trials 5 y postapproval, likelihood of publication correlated with statistically significant results (odds ratio [OR] 3.03, 95% confidence interval [CI] 1.78–5.17); larger sample sizes (OR 1.33 per 2-fold increase in sample size, 95% CI 1.17–1.52); and pivotal status (OR 5.31, 95% CI 3.30–8.55). In multivariable logistic regression for only the pivotal trials 5 y postapproval, likelihood of publication correlated with statistically significant results (OR 2.96, 95% CI 1.24–7.06) and larger sample sizes (OR 1.47 per 2-fold increase in sample size, 95% CI 1.15–1.88). Statistically significant results and larger sample sizes were also predictive of publication at 2 y postapproval and in multivariable Cox proportional models for all trials and the subset of pivotal trials. Over half of all supporting trials for FDA-approved drugs remained unpublished ≥ 5 y after approval. Pivotal trials and trials with statistically significant results and larger sample sizes are more likely to be published. Selective reporting of trial results exists for commonly marketed drugs. Our data provide a baseline for evaluating publication bias as the new FDA Amendments Act comes into force mandating basic results reporting of clinical trials.

17 July 2019 in BMC Medicine
Verified
Journal Article
Open access
PDF file
EHEric B. Hekler
Eric B. Hekler
PKPredrag Klasnja
Predrag Klasnja
GCGuillaume Chevance
Guillaume Chevance
NGNatalie M. Golaszewski
Natalie M. Golaszewski
DLDana Lewis
Dana Lewis
ISIda Sim
Ida Sim
There is great interest in and excitement about the concept of personalized or precision medicine and, in particular, advancing this vision via various ‘big data’ efforts. While these methods are necessary, they are insufficient to achieve the full personalized medicine promise. A rigorous, complementary ‘small data’ paradigm that can function both autonomously from and in collaboration with big data is also needed. By ‘small data’ we build on Estrin’s formulation and refer to the rigorous use of data by and for a specific N-of-1 unit (i.e., a single person, clinic, hospital, healthcare system, community, city, etc.) to facilitate improved individual-level description, prediction and, ultimately, control for that specific unit. The purpose of this piece is to articulate why a small data paradigm is needed and is valuable in itself, and to provide initial directions for future work that can advance study designs and data analytic techniques for a small data approach to precision health. Scientifically, the central value of a small data approach is that it can uniquely manage complex, dynamic, multi-causal, idiosyncratically manifesting phenomena, such as chronic diseases, in comparison to big data. Beyond this, a small data approach better aligns the goals of science and practice, which can result in more rapid agile learning with less data. There is also, feasibly, a unique pathway towards transportable knowledge from a small data approach, which is complementary to a big data approach. Future work should (1) further refine appropriate methods for a small data approach; (2) advance strategies for better integrating a small data approach into real-world practices; and (3) advance ways of actively integrating the strengths and limitations from both small and big data approaches into a unified scientific knowledge base that is linked via a robust science of causality. Small data is valuable in its own right. That said, small and big data paradigms can and should be combined via a foundational science of causality. With these approaches combined, the vision of precision health can be achieved.

9 August 2012 in Journal of Medical Internet Research
Verified
Journal Article
Open access
CCConnie Chen
Connie Chen
DHDavid Haddad
David Haddad
JSJoshua Selsky
Joshua Selsky
JHJulia E Hoffman
Julia E Hoffman
RKRichard L Kravitz
Richard L Kravitz
ISIda Sim
Ida Sim
Journal of Medical Internet Research - International Scientific Journal for Medical Research, Information and Communication on the Internet

20 March 2020 in Science
Verified
Journal Article
Closed access
ISIda Sim
Ida Sim
MSMichael Stebbins
Michael Stebbins
BBBarbara E. Bierer
Barbara E. Bierer
ABAtul J. Butte
Atul J. Butte
JDJeffrey Drazen
Jeffrey Drazen
RLRebecca Li
Rebecca Li
A draft policy is generally supportive but should start mandating data sharing

13 November 2013 in Journal of Biomedical Informatics
Verified
Journal Article
Closed access
ISIda Sim
Ida Sim
STSamson W. Tu
Samson W. Tu
SCSimona Carini
Simona Carini
HLHarold P. Lehmann
Harold P. Lehmann
BPBrad H. Pollock
Brad H. Pollock
KWKnut M. Wittkowski
Knut M. Wittkowski